These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32892343)

  • 1. Infantile bullous pemphigoid following serogroup B meningococcal vaccination.
    Navarro-Navarro I; Jiménez-Gallo D; Valenzuela-Ubiña S; Domínguez-Gomez M; Linares-Barrios M
    Br J Dermatol; 2021 Mar; 184(3):e53. PubMed ID: 32892343
    [No Abstract]   [Full Text] [Related]  

  • 2. First immunogenicity data for the UK serogroup B meningococcal vaccination schedule in infants.
    McNamara LA; Mbaeyi S
    Lancet Infect Dis; 2021 May; 21(5):586-587. PubMed ID: 33428869
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 4. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal disease: Can we predict the unpredictable?
    Martinón-Torres F; Trilla A
    Med Clin (Barc); 2020 Jan; 154(1):20-22. PubMed ID: 31350058
    [No Abstract]   [Full Text] [Related]  

  • 6. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serogroup B meningococcal disease during Hajj: preparing for the worst scenario.
    Khalil MK; Borrow R
    Travel Med Infect Dis; 2009 Jul; 7(4):231-4. PubMed ID: 19717106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the burden of serogroup C meningococcal disease in England and Wales.
    Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
    Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pros and cons of vaccination against serogroup B meningococcal disease.
    Delgado Rodríguez M; Domínguez García Á
    Med Clin (Barc); 2018 Feb; 150(3):109-113. PubMed ID: 28992986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak.
    McNamara LA; Shumate AM; Johnsen P; MacNeil JR; Patel M; Bhavsar T; Cohn AC; Dinitz-Sklar J; Duffy J; Finnie J; Garon D; Hary R; Hu F; Kamiya H; Kim HJ; Kolligian J; Neglia J; Oakley J; Wagner J; Wagner K; Wang X; Yu Y; Montana B; Tan C; Izzo R; Clark TA
    Pediatrics; 2015 May; 135(5):798-804. PubMed ID: 25917990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Brief: New meningococcal serogroup B vaccination recommendations.
    Med Lett Drugs Ther; 2020 Nov; 62(1612):191-192. PubMed ID: 33443493
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of Mass Vaccination Clinics in Response to a Serogroup B Meningococcal Disease Outbreak at a Large, Public University-Oregon, 2015.
    Fisher EA; Poissant T; Luedtke P; Leman R; Young C; Cieslak P
    J Adolesc Health; 2018 Aug; 63(2):151-156. PubMed ID: 30149923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review.
    Nwogu IB; Jones M; Langley T
    Vaccine; 2021 Apr; 39(16):2201-2213. PubMed ID: 33744052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An effective serogroup B meningococcal vaccine.
    Domínguez F; Menéndez J; Ochoa R
    Vaccine; 2006 Nov; 24(49-50):7025-6. PubMed ID: 16879900
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to: Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact.
    Wassil J; Huels J; Narasimhan V
    Vaccine; 2014 May; 32(25):2943. PubMed ID: 23962533
    [No Abstract]   [Full Text] [Related]  

  • 16. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 17. A Review of the Epidemiology of Invasive Meningococcal Disease and Vaccination Strategies in North Africa.
    Taha MK; Presa J; Serra L
    Int J Infect Dis; 2021 Mar; 104():189-197. PubMed ID: 33227521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016.
    Soeters HM; Whaley M; Alexander-Scott N; Kanadanian KV; MacNeil JR; Martin SW; McNamara LA; Sicard K; Vanner C; Vuong J; Wang X; Bandy U; Patel M;
    Clin Infect Dis; 2017 Apr; 64(8):1115-1122. PubMed ID: 28158417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
    Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
    Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
    de Moraes JC; Perkins BA; Camargo MC; Hidalgo NT; Barbosa HA; Sacchi CT; Landgraf IM; Gattas VL; Vasconcelos Hde G
    Lancet; 1992 Oct; 340(8827):1074-8. PubMed ID: 1357461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.